Precise. Personalized. Predictive.
Venebio Opioid Advisor Clinical Decision Support
Over the last two decades, prescription opioid-related overdose and deaths from opioid-induced respiratory depression (OIRD) have emerged as a major public health threat in the United States. Overdose deaths involving prescription opioids have quadrupled since 1999 and parallel the striking increase of U.S. sales and consumption of prescription opioids. From 1999 to 2015, more than 183,000 people have died in the U.S. from overdoses related to prescription opioids.
More about the opioid overdose epidemic.
In response to the public health threat posed by the opioid overdose epidemic, Venebio Group developed the Venebio Opioid Advisor (VOA) clinical decision support tool to support safer opioid prescribing.
The tool provides an evidence-based, quantitative estimate of a patient’s likelihood of experiencing a life-threatening opioid emergency in the next six months. It characterizes the patient’s specific risk factor profile and provides individualized, evidence-based, risk-mitigation interventions for the health care professional and patient.
More about Venebio Opioid Advisor.
The development of VOA built on our previously published predictive models and scoring systems that estimate the level of risk of experiencing an adverse outcome.
VOA has undergone extensive retrospective validation, initially in a case-control study of U.S. military veterans, followed by validation in a more representative population using the IMS PharMetrics Plus™ database of 18+ million prescription opioid users.
More about our research.
Eleven states are already allowing unilateral dispensing of Naloxone by a pharmacist. Most others allow dispensing without prescription or have standing order policies. Only five states have not allowed special access to naloxone. This link shows an updated map of naloxone access in community pharmacies across the United States, as of […]
The opioid epidemic killed more than 33,000 people in 2015. What follows are stories of a national affliction that has swept the country, from cities on the West Coast to bedroom communities in the Northeast. Read the article here.
Interesting article on a fentanyl (Subsys) scam that is worth a read. There is substantial focus on fentanyl currently; this kind of “pill-mill” and pay-for-prescribing behavior drives focus and decision-making for payers and for regulators. This article presents a slightly different angle on the opioid challenge.
Venebio Group, LLC, was featured on the cover of the Richmond Times-Dispatch Metro Business Section. The accompanying article highlights the recent $1.5 million NIH grant for continual development of the Venebio Opioid Advisor. Click here to read the full article.
Venebio received a $1.5M SBIR grant from the National Institute on Drug Abuse to continue its development of the Venebio Opioid Advisor and fight the national opioid epidemic. Read the full news release here.